Bullish Case: RVMD's flat term structure (Helium IV ~41% Oct rising to ~50% Aug-2027) with calls out-trading puts by 52% and bullish risk 21% above bearish suggests continued franchise repricing on RAS(ON) commercialization momentum. Helium's +3.24% forecast and put-skew monetization favor slow upward drift; prior underestimation of upside (missed $211 vs $155-175 target) argues against fading strength.

Bearish Case: RVMD is -7.3% in a month with insider sales (Kelsey $18.7M Sept 11), a +588% five-year run pricing in heavy execution, and 60%+ IV on deep-OTM puts signaling crash-hedging demand. Density mass below $195 (market pdf peaks at 190-195) and October put volume dominance (200P, 220P) show protection buyers still pay up—any data slip or SPY vol shock could unwind the premium.

Potential Outcomes: 45%: $190-215 chop into Nov 21 expiry; falsifiable if IV mean-reverts while spot holds $195+ (return-surface densest band).
25%: >$225 on positive clinical/commercial headline; check call IV (230C at 44%) expanding with gap.
20%: $165-190 on catalyst disappointment or financing noise; falsifiable if 170-190P IV stays bid while spot slides.
7%: >$250 on buyout/partnership confirmation.
3%: <$160 with macro vol shock; SPY surface tail widening is the tell.

Trading Oracle: Sign Up to access trading oracle trade ideas.

September 26, 2026